Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Extension Study of GW906 in Essential Hypertension
NCT07879755Recruiting
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Start
- Jun 2026
- Primary completion
- Jan 2029
- Countries
- 1
01
Overview
Open-label, single-arm trial of GW906 in essential hypertension, sponsored by Shenzhen Salubris Pharmaceuticals Co., Ltd. Primary endpoint: Incidence of treatment-emergent adverse events up to 3 years. Started Jun 2026; status: recruiting.
02
Drugs
GW906
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT07879755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07879755.